Phase 3 Ebola Vaccines Clinical Study Conference Opens in Conakry

0
795
Untitled-6.jpg

A two-day regional conference aimed at exploring the possibility of expanding the Phase 3 component of the ongoing Ebola Vaccines Clinical study in Liberia to Sierra Leone and Guinea opened yesterday, June 11, in Conakry, Guinea.

A delegation of Liberian physicians, scientists, and clinical researchers will meet with their counterparts from Sierra Leone and Guinea to seek collaboration and cooperation on vaccines and therapeutic clinical trials against the deadly Ebola Virus through a multi-country regional strategy.

The Liberian delegation is headed by Dr. Moses B. F. Massaquoi, Chair, National Case Management, Ministry of Health and Liberian Principal Investigator for the ZMapp clinical trial. The delegation also includes Drs. Stephen Kennedy and Fatorma

Bolay, Co-Principal Investigators for (PREVAIL I), the Liberian Ebola vaccine clinical study; Dr. Eugene Dolopei, Chief Medical Officer for SOS Hospital and member of the technical team for the Liberia-U.S Clinical Research Partnership (PREVAIL); and Mrs. Wissedi Sio-Njoh, Director of Operations for PREVAIL.

“This strategy creates an opportunity for current and future collaborations in transferring and/or sharing technologies on prevention, treatment and research among others to eliminate the Ebola Virus Disease and other related epidemics from within the Mano River Basin,” noted Dr. Kennedy.

Representatives from the Ministries of Health of the participating countries, as well as partners from the U.S. National Institute of Health (NIH), World Health Organization (WHO), the French National Institute of Health & Medical Research (INSERM), the

U.S. Centers for Disease Control & Prevention (CDC); and pharmaceutical manufacturers Glaxo SmithKline (GSK) and Merck/NewLink, are expected to be in attendance.

“There appears to be a consensus that the window of opportunity is closing for potential answers to research questions regarding effective vaccines and therapeutic options,” said Dr. Massaquoi. “We believe that the development of effective vaccines and treatments for Ebola can be achieved through this sort of regional partnership and multi-country research collaboration.”

Authors

LEAVE A REPLY

Please enter your comment!
Please enter your name here